BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36852480)

  • 1. A parasitic fungus employs mutated eIF4A to survive on rocaglate-synthesizing
    Chen M; Kumakura N; Saito H; Muller R; Nishimoto M; Mito M; Gan P; Ingolia NT; Shirasu K; Ito T; Shichino Y; Iwasaki S
    Elife; 2023 Feb; 12():. PubMed ID: 36852480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species.
    Agarwal G; Chang LS; Soejarto DD; Kinghorn AD
    Planta Med; 2021 Oct; 87(12-13):937-948. PubMed ID: 33784769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translation Inhibition by Rocaglates Activates a Species-Specific Cell Death Program in the Emerging Fungal Pathogen Candida auris.
    Iyer KR; Whitesell L; Porco JA; Henkel T; Brown LE; Robbins N; Cowen LE
    mBio; 2020 Mar; 11(2):. PubMed ID: 32156828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
    Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
    Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rocaglates as dual-targeting agents for experimental cerebral malaria.
    Langlais D; Cencic R; Moradin N; Kennedy JM; Ayi K; Brown LE; Crandall I; Tarry MJ; Schmeing M; Kain KC; Porco JA; Pelletier J; Gros P
    Proc Natl Acad Sci U S A; 2018 Mar; 115(10):E2366-E2375. PubMed ID: 29463745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F.
    Chu J; Zhang W; Cencic R; O'Connor PBF; Robert F; Devine WG; Selznick A; Henkel T; Merrick WC; Brown LE; Baranov PV; Porco JA; Pelletier J
    Cell Rep; 2020 Feb; 30(8):2481-2488.e5. PubMed ID: 32101697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates.
    Obermann W; Azri MFD; Konopka L; Schmidt N; Magari F; Sherman J; Silva LMR; Hermosilla C; Ludewig AH; Houhou H; Haeberlein S; Luo MY; Häcker I; Schetelig MF; Grevelding CG; Schroeder FC; Lau GSK; Taubert A; Rodriguez A; Heine A; Yeo TC; Grünweller A; Taroncher-Oldenburg G
    Sci Rep; 2023 Jun; 13(1):9297. PubMed ID: 37291191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
    Zhang X; Bi C; Lu T; Zhang W; Yue T; Wang C; Tian T; Zhang X; Huang Y; Lunning M; Hao X; Brown LE; Devine WG; Vose J; Porco JA; Fu K
    Leukemia; 2020 Jan; 34(1):138-150. PubMed ID: 31171817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic Rocaglate Derivatives from Leaves of Aglaia perviridis.
    An FL; Wang XB; Wang H; Li ZR; Yang MH; Luo J; Kong LY
    Sci Rep; 2016 Jan; 6():20045. PubMed ID: 26818797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors.
    Zhang W; Chu J; Cyr AM; Yueh H; Brown LE; Wang TT; Pelletier J; Porco JA
    J Am Chem Soc; 2019 Aug; 141(32):12891-12900. PubMed ID: 31310112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity.
    Obermann W; Friedrich A; Madhugiri R; Klemm P; Mengel JP; Hain T; Pleschka S; Wendel HG; Hartmann RK; Schiffmann S; Ziebuhr J; Müller C; Grünweller A
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
    Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
    Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the Effects of Rocaglates on Energy Metabolism and Immune Modulation on Cells of the Human Immune System.
    Schiffmann S; Henke M; Seifert M; Ulshöfer T; Roser LA; Magari F; Wendel HG; Grünweller A; Parnham MJ
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the targeting spectrum of rocaglates among eIF4A homologs.
    Naineni SK; Cencic R; Robert F; Brown LE; Haque M; Scott-Talib J; Sénéchal P; Schmeing TM; Porco JA; Pelletier J
    RNA; 2023 Jun; 29(6):826-835. PubMed ID: 36882295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.
    Iwasaki S; Iwasaki W; Takahashi M; Sakamoto A; Watanabe C; Shichino Y; Floor SN; Fujiwara K; Mito M; Dodo K; Sodeoka M; Imataka H; Honma T; Fukuzawa K; Ito T; Ingolia NT
    Mol Cell; 2019 Feb; 73(4):738-748.e9. PubMed ID: 30595437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
    Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
    Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A forward genetic screen identifies modifiers of rocaglate responsiveness.
    Shen L; Pugsley L; Cencic R; Wang H; Robert F; Naineni SK; Sahni A; Morin G; Zhang W; Nijnik A; Porco JA; Langlais D; Huang S; Pelletier J
    Sci Rep; 2021 Sep; 11(1):18516. PubMed ID: 34531456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.
    Taroncher-Oldenburg G; Müller C; Obermann W; Ziebuhr J; Hartmann RK; Grünweller A
    Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33807988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
    Iwasaki S; Floor SN; Ingolia NT
    Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.